

Error Estimates for Calculated Glomerular Filtration Rates

Simon Brown

Abstract—Glomerular filtration rate (GFR) is a measure of kidney function. It is usually estimated from serum concentrations of cystatin C or creatinine although there has been considerable debate in the literature about (i) the best equation to use and (ii) the variability in the correlation between the concentrations of creatinine and cystatin C. The equations for GFR can be written in a general form and from these I calculate the error of the GFR estimates associated with analyte measurement error. These show that the error of the GFR estimates is such that it is not possible to distinguish between the equations over much of the concentration range of either analyte. The general forms of the equations are also used to derive an expression for the concentration of cystatin C as a function of the concentration of creatinine. This equation shows that these analyte concentrations are not linearly related. Clinical reports of cystatin C and creatinine concentration are consistent with the expression derived.

Keywords—creatinine, cystatin C, error analysis, glomerular filtration rate, measurement error.

I. INTRODUCTION

GLOMERULAR filtration rate (GFR) is a well established measure of kidney function. Values decline with age and depend on gender, but are about 120-130 mL min⁻¹ (1.73 m²)⁻¹ in healthy young adults. In chronic kidney disease (CKD) GFR declines and reaches values of less than 15 mL min⁻¹ (1.73 m²)⁻¹ in stage 5 CKD. Estimates of GFR are often used in the detection, evaluation and management of CKD [7].

The GFR is the volume of fluid filtered through the glomerular capillaries of the kidney into Bowman's capsule in a given time. This can be measured by comparing the concentration of an analyte in the blood (C_{blood}) and the urine (C_{urine}) for a given urine volume (V_{urine} , which has units of mL min⁻¹)

$$\text{GFR} = \frac{C_{\text{urine}}}{C_{\text{blood}}} V_{\text{urine}} \quad (1)$$

and it is usually expressed per unit body surface area (so the usual units are mL min⁻¹ (1.73 m²)⁻¹), which can be estimated in m² from height (h , in cm) and weight (w , in kg) using

$$A_{\text{body}} = 0.007184 h^{0.725} w^{0.425} \quad (2)$$

[10], for example. Several analytes have been used to estimate GFR, but the distribution of exogenous compounds

such as inulin, diethylene triamine pentaacetic acid or iothalamate [14] are expensive and difficult to employ in normal clinical practice [7]. Instead, endogenous markers, including creatinine and cystatin C, have been used. Unfortunately, the concentration of these analytes varies with age, gender and physiological conditions. Creatinine, especially, has complex chemistry and biochemistry [15, 16], the concentration varies with muscle mass and physical activity [17] and assay results can be affected by the presence in the sample of common drugs [18]. Moreover, it has been argued that creatinine is not a sensitive indicator of GFR [19-21]. Cystatin C concentration is also variable [22], but the variation with age and gender is less pronounced than that reported for creatinine in at least some cases [23]. The correlation between the concentrations of creatinine and cystatin C can be weak ($r = 0.18$) [22-25] or relatively strong ($r = 0.9$) [26].

Many equations are used to estimate GFR, but they are all based on laboratory measurements of either cystatin C or serum creatinine, although the latter expressions often involve other measurements (usually age and weight, but also serum urea nitrogen or albumin). Several recent publications have compared these equations and, in most cases, one equation is identified as superior to the others [3, 27-32].

As one would anticipate, all the comparable equations yield similar estimates. This prompts one to ask whether they can be distinguished given the uncertainty of the laboratory measurements on which they are based. The equations are based on statistical analysis, but it appears that each input analyte value is treated as error-free.

No analytical estimate of the uncertainty of the GFR estimates has been reported in the literature. This omission is rectified here. I show that the uncertainty of the GFR estimates arising just from the laboratory measurements makes them effectively indistinguishable. It is, therefore, not reasonable to suggest that any one equation is more reliable than any other until more precise analytical techniques become available. I also show that the variability in the correlation between cystatin C and creatinine concentration is consistent with the GFR equations.

II. GENERAL FORM OF THE EQUATIONS

To simplify the analysis, and for clarity, I write the GFR equations in general form. This makes it possible to analyse the various equations based on a specific analyte once, which

S. Brown is with the School of Human Life Sciences, University of Tasmania, Launceston, Tasmania 7250, Australia (phone: +61-3-63245467; fax: +61-3-63243995; e-mail: Simon.Brown@utas.edu.au).

TABLE I
COEFFICIENT VALUES FOR SOME CYSTATIN C-BASED ESTIMATES OF GFR (3)

Model	α_0	α_1	γ
Filler and Lepage ^a [2]	0	$10^{1.962}$	1.123
Hoek <i>et al.</i> [3]	-4.32	80.35	1
Larsson <i>et al.</i> [5]	0	77.24	1.2623
Le Bricon <i>et al.</i> [9]	4	78	1
Rule <i>et al.</i> [12]			
transplant recipients	0	76.6	1.16
native CKD	0	66.8	1.30

^a The Filler and Lepage [2] equation is usually expressed as $\log_{10}(\text{GFR})$.

is especially important since each author can have variants for different conditions, for example Rule *et al.* [12] report cystatin C-based equations for individuals living with CKD and for kidney transplant recipients (Table I).

The cystatin C-based equations all take the form [33]

$$\text{GFR}(c) = \alpha_0 + \alpha_1 c^{-\gamma} \quad (3)$$

where c is the concentration of cystatin C (mg L^{-1}) and α_0 , α_1 and γ are constants specific to each variant of the equation (Table I).

The serum creatinine-based equations take the form

$$\text{GFR}(n, b, r) = \beta_0 + \beta_1 f(y, w, h, g, e) n^{\gamma_n} b^{\gamma_b} r^{-\gamma_r} \quad (4)$$

where y , w , h , g and e are age, weight, height, gender and ethnicity (whether Afro-American for example), respectively. The laboratory measurements are blood urea nitrogen (n), albumin (b) and serum creatinine (r). I assume that y , w , g and e can be determined accurately, so they contribute no significant error to the estimate of GFR and that $\beta_1 f(y, w, h, g, e)$ can be treated as a constant for particular cohorts. The constants (the γ s) and $\beta_1 f(\cdot)$ are specific to each variant of the equation (Table II).

The entries in Tables I and II have been selected from a very large and growing number of equations, each of which appears to have the same form as (3) and (4).

III. UNCERTAINTY OF GFR ESTIMATES

Equations (3) and (4) depend on one or more laboratory measurements which inevitably have uncertainty. Ignoring any other source of error in estimating GFR, the uncertainty in the laboratory data can be used to estimate the uncertainty of the GFR estimates obtained from (3) and (4). This involves

the standard Taylor series approach to error analysis [34].

A. Cystatin C-based estimates

From (3) the uncertainty in the GFR estimate due to the uncertainty in the laboratory measurement of cystatin C (u_c) is

$$u_{\text{GFR}(c)} = \gamma (\text{GFR}(c) - \alpha_0) \frac{u_c}{c} \quad (5)$$

Here the uncertainty (u_x) is the standard deviation (s) or variance (s^2) of x . There are many reports of the coefficients of variation for cystatin C measurements. Some of these are shown in Fig. 1, from which it is clear that s is proportional to the concentration of cystatin C and that the average coefficient of variation (CV) is about 0.046. Since the CV for cystatin C measurements is s/c , (5) yields

$$s_{\text{GFR}(c)} \approx 0.046 \gamma (\text{GFR}(c) - \alpha_0) \quad (6)$$

which is an approximation of the standard deviation of the estimate of GFR due to the error in the estimation of cystatin C alone. For all the GFR equations in Table I, except that of Le Bricon *et al.* [9], $\alpha_0 \leq 0$ and so $s_{\text{GFR}(c)} > 0.046 \text{GFR}(c)$ since $\gamma \geq 1$.




Fig. 1. Relationship between cystatin C concentration and estimated standard deviation of the measurement (s). The solid line is the regression line ($s = (0.006 \pm 0.01) + (0.046 \pm 0.003) \times [\text{cystatin C}]$, $r^2 = 0.97$) and the dashed lines represent the 95% confidence band. Estimates of s were obtained from six randomly selected studies in which the cystatin C assay was characterised: \blacklozenge - [35]; \bullet - [36]; \circ -

TABLE II
COEFFICIENT VALUES FOR SOME SERUM CREATININE-BASED ESTIMATES OF GFR (4)

Model	β_0	$\beta_1 f(\cdot)$	γ_n	γ_b	γ_r
Cockcroft and Gault ^a [1]	0	$0.85^g \times (140 - y) \times w \times 1.73 / (72 \times A_{\text{body}})$	0	0	1
MDRD 1 [4]	0	$170 \times 0.762^g \times 1.18^e y^{-0.176}$	-0.170	0.318	0.999
MDRD 2 [6]	0	$186 \times 0.742^g \times 1.212^e y^{-0.203}$	0	0	1.154
Jelliffe 1 [8]	0	$0.90^g \times [98 - 0.8 \times (y - 20)]$	0	0	1
Jelliffe 2 [11]	$-6^g - 11^{1-g}$	$80^g \times 100^{1-g}$	0	0	1
Salazar-Corcoran ^b [13]	0	$60^g \times 51^{g-1} \times (137^{1-g} \times 146^g - y) \times (0.285^{1-g} \times 0.287^g \times w + 10^{-4} \times 9.74^g \times 12.1^{1-g} \times h^2)$	0	0	1
Rule <i>et al.</i> (native CKD) [12]	0	$273 \times 0.738^g \times y^{-0.299}$	0	0	1.22

Gender is specified by $g = 1$ for females and $g = 0$ for males. Ethnicity is specified by $e = 1$ for Afro-Americans and $e = 0$ otherwise.

^a A_{body} is given by (2).

^b The factor of 10^{-4} is necessary to convert h from cm to m.

[37]; ▲-[38]; ▼- [39]; ■- [40].

The difference between estimates of GFR obtained from two forms of (3) is

$$\begin{aligned} \Delta \text{GFR}(c) &= \alpha_0 - \alpha'_0 + \alpha_1 c^{-\gamma} - \alpha'_1 c^{-\gamma'} \\ &= \Delta \alpha_0 + \left(1 - \frac{\alpha'_1}{\alpha_1} c^{\gamma-\gamma'}\right) (\text{GFR}(c) - \alpha_0), \end{aligned} \quad (7)$$

where the second form of (3) is indicated by the prime. The relative error is

$$\frac{\Delta \text{GFR}(c)}{\text{GFR}(c)} \approx \frac{\Delta \text{GFR}(c) - \Delta \alpha_0}{\text{GFR}(c) - \alpha_0} = 1 - \frac{\alpha'_1}{\alpha_1} c^{\gamma-\gamma'} \quad (8)$$

where $0 \leq |\gamma - \gamma'| \leq 0.30$ and $0.73 \leq \alpha'_1/\alpha_1 \leq 1.37$ based on Table I.

B. Creatinine-based estimates

Similarly, the uncertainty in the GFR estimate arising from the uncertainty in the laboratory measurement of serum urea nitrogen (u_n), albumin (u_b) and creatinine (u_r) can be calculated from (4)

$$\begin{aligned} u_{\text{GFR}(r)} &= \sqrt{\left(\frac{\partial \text{GFR}}{\partial n}\right)^2 u_n^2 + \left(\frac{\partial \text{GFR}}{\partial b}\right)^2 u_b^2 + \left(\frac{\partial \text{GFR}}{\partial r}\right)^2 u_r^2} \\ &= (\text{GFR}(n, b, r) - \beta_0) \times \\ &\quad \sqrt{\left(\gamma_n \frac{u_n}{n}\right)^2 + \left(\gamma_b \frac{u_b}{b}\right)^2 + \left(\gamma_r \frac{u_r}{r}\right)^2} \end{aligned} \quad (9)$$

Of course, if the uncertainties are taken to be standard deviations, u_n/n , u_b/b and u_r/r are just the CVs for serum urea nitrogen, albumin and creatinine, which are about 0.038 [41], 0.029 [41] and 0.028 (Fig. 2), respectively. The CV for creatinine used here is strongly influenced by the highest value in Fig. 2, but when that datum is removed the estimated CV increases to 0.033, so it has been retained to provide a more conservative estimate of the error. Since $|\gamma_n| < \gamma_b < \gamma_r$, serum urea nitrogen and albumin combined contribute only 7.6% of $u_{\text{GFR}(r)}$, and so, based on the error of the creatinine measurement alone,

$$s_{\text{GFR}(r)} \approx 0.028 \gamma_r (\text{GFR}(r) - \beta_0). \quad (10)$$

In addition to the measurement of serum analytes, values for age (y), weight (w), height (h), gender (g) and 'ethnicity' (e) are also required in (4). Such anthropometric data are available from the United States National Health and Nutrition Examination Survey (NHANES) [42].

By analogy with (7), the difference between estimates of GFR obtained from two forms of (4) is

$$\begin{aligned} \Delta \text{GFR}(r) &= \beta_0 - \beta'_0 + p c^{-\gamma_r} - p' c^{-\gamma'_r} \\ &= \Delta \beta_0 + \left(1 - \frac{p'}{p} c^{\gamma_r - \gamma'_r}\right) (\text{GFR}(r) - \beta_0), \end{aligned} \quad (11)$$

where p and p' are the appropriate forms of $\beta_i f(\cdot)$ from Table II. The relative error follows naturally from (8) and (11)

$$\frac{\Delta \text{GFR}(r)}{\text{GFR}(r)} \approx \frac{\Delta \text{GFR}(r) - \Delta \beta_0}{\text{GFR}(r) - \beta_0} = 1 - \frac{p'}{p} c^{\gamma_r - \gamma'_r}, \quad (12)$$

where $0 \leq |\gamma_r - \gamma'_r| \leq 0.221$ and it is more difficult to set

bounds on p'/p because of its complexity (Table II).




Fig. 2. Relationship between creatinine concentration and estimated standard deviation of the measurement (s). The solid line is the regression line ($s = (-0.007 \pm 0.003) + (0.028 \pm 0.002) \times [\text{creatinine}]$, $r^2 = 0.98$) and the dashed lines represent the 95% confidence band. Estimates of s were obtained from six randomly selected studies in which the creatinine assay was characterised: ◆- [43]; ●- [38]; ○- [44]; ▲- [39]; ▼- [24]; ■- [21]. The highest datum does strongly influence the regression, but it is included to provide a conservative estimate of the CV as described in the text.

IV. RESULTS

A. Cystatin C-based estimates

Glomerular filtration rate declines with increasing c (Fig 3A) and all of the forms of (3) listed in Table I are indistinguishable at low c (Fig 3B), as I have shown elsewhere [33] in a different way. However, as c increases, the Filler and Lepage [2] and the transplant recipient form of the Rule *et al.* [12] equations become statistically distinguishable from the others (these are the upper two curves in Fig. 3, A and B).

B. Creatinine-based estimates

Glomerular filtration rate declines with increasing r (Fig. 4A) and all of the forms of (4) listed in Table II except the Salazar-Corcoran expression [13] are indistinguishable at moderate r (Fig. 4B). However, as r decreases or increases, it is clear that some forms of (4) become statistically distinguishable (Fig. 4, A and B).

C. The creatinine-cystatin C correlation

The variability in the correlation between c and r [22-26] can be rationalised by equating (3) and (4) to obtain

$$c = \left(\frac{\alpha_1 r^{\gamma_r}}{(\beta_0 - \alpha_0) r^{\gamma_r} + \beta_1 f(\cdot)} \right)^{1/\gamma} \quad (13)$$

which can be a concave or convex function depending on the parameter values. For some, but not all, forms of (3) and (4), it is clear from Tables I and II that $\alpha_0 = \beta_0 = 0$, in which case (13) becomes

$$c \approx \left(\frac{\alpha_1}{\beta_1 f(\cdot)} \right)^{1/\gamma} r^{\gamma_r/\gamma}, \quad (14)$$




Fig. 3. Relationship between GFR calculated using (3) and cystatin C concentration using the coefficients in Table I (A) and (B) the differences between the GFR estimates and that of Larsson *et al.* [5] (7). In each case, the grey band represents the approximate 95% confidence interval (based on (6)) for the Larsson *et al.* [5] form of (3), each of the other forms also has a confidence interval, but none of these is shown for clarity. Note that the concentration of cystatin C is plotted on a logarithmic scale for clarity. The upper two curves are the Rule *et al.* [12] transplant recipient (····) and Filler and Lepage [2] (---) expressions. The bottom curve is the Rule *et al.* [12] native CKD expression (---). The horizontal dashed line (---) in (B) corresponds to the expression of Larsson *et al.* [5].

which also applies at small values of r , if $\beta_0 - \alpha_0 > 0$. In either of these circumstances, the correlation between c and r will be high. At high r , (13) asymptotically approaches

$$c \approx \left(\frac{\alpha_1}{\beta_0 - \alpha_0} \right)^{1/\gamma}, \quad (15)$$

in which case the correlation coefficient would tend towards zero. So, one implication of (13) is that the correlation coefficient between r and c can be zero at high r and approach 1 at low r . A second implication is that variability in the strength of the relationship between c and r is to be expected.

V. DISCUSSION

Small errors are inherent in the measurements of creatinine and cystatin C (Figs 1 and 2), but they tend to be neglected when estimating GFR and are often not even reported [45]. They can be sufficient to make it difficult to distinguish the cystatin C-based expressions (3) or some of the creatinine-based expressions (4) used to calculate GFR (Figs 3 and 4).

This need not invalidate statistical comparison of the equations [3, 27-32], but does prompt the suggestion the confounding effects of the measurement error should be considered.




Fig. 4. Relationship between GFR calculated using (4) and creatinine concentration using the coefficients in Table II (A) and (B) the differences between the GFR estimates and the MDRD 2 [6] equation (11). The anthropometric data required ($w = 84.5$ kg, $h = 177.6$ cm) were obtained from NHANES [42], for $y = 24.5$ and $g = e = 0$. The grey band represents the approximate 95% confidence interval (based on (10)) for the MDRD 2 [6] form of (4), each of the other forms also has a confidence interval, but none of these are shown for clarity. Note that the concentration of creatinine is plotted on a logarithmic scale for clarity. The curves are the Jelliffe equations [8, 11] (····), the Cockcroft and Gault equation [1] (—) and that of Rule *et al.* [12] (-·-·-). The upper dashed curve (---) in (A) is the Salazar-Corcoran [13] equation which has been omitted from (B). The central dashed curve (---) is the MDRD 2 equation [6].

The variability in the correlation between the concentrations of cystatin C and creatinine [22-26] is qualitatively consistent with (13). Moreover, the data reported by Yashiro *et al.* [26] are at least partly quantitatively consistent with (13). For example, comparison of (14) with their regression data indicates that $\gamma_r/\gamma = 0.799$, which is within the range of $\gamma_r/\gamma \in [0.768, 1.22]$ calculable from Tables I and II. The same comparison yields $(\alpha_1/\beta_1 f(\cdot))^{1/\gamma} = 1.28$, which could be consistent with the accessible range of $\alpha_1/\beta_1 f(\cdot)$ depending on the combination of age, weight and height of the individual (Table II) and given $\gamma \geq 1$ (Table I).

It has been argued that serum creatinine is a poor early indicator of kidney dysfunction [19, 20] and that GFR can decline by half before any significant increase in serum creatinine is observed. However, the sensitivity of GFR to c or r can be estimated from (3) and (4), respectively as

$$\frac{\partial \ln \text{GFR}(c)}{\partial \ln c} = -\gamma \frac{\text{GFR}(c) - \alpha_0}{\text{GFR}(c)} \approx -\gamma \quad (16)$$

and

$$\frac{\partial \ln \text{GFR}(r)}{\partial \ln r} = -\gamma_r \frac{\text{GFR}(r) - \beta_0}{\text{GFR}(r)} \approx -\gamma_r \quad (17)$$

Since $\gamma_r \approx \gamma$ (Tables I and II), this indicates that the cystatin C-based and creatinine-based GFR expressions should be similarly sensitive. However, the variation in c with age and gender is less pronounced than that reported for r in at least some cases [23], which may contribute to the assessment of the sensitivity of GFR.

In the identification of the best means of estimating GFR in clinical practice, analyte measurement error should be considered. Moreover further analysis of the relationship between the concentrations of cystatin C and creatinine (13) is warranted.

REFERENCES

- [1] D. W. Cockcroft and M. H. Gault, "Prediction of creatinine clearance from serum creatinine," *Nephron*, vol. 16, pp. 31-41, 1976.
- [2] G. Filler and N. Lepage, "Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?," *Pediatric Nephrology*, vol. 18, pp. 981-985, 2003.
- [3] F. J. Hoek, F. A. W. Kemperman, and R. T. K. Krediet, "A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate," *Nephrology Dialysis Transplantation*, vol. 18, pp. 2024-2031, 2003.
- [4] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.," *Annals of Internal Medicine*, vol. 130, pp. 461-470, 1999.
- [5] A. Larsson, J. Malm, A. Grubb, and L.-O. Hansson, "Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L," *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 64, pp. 25-30, 2004.
- [6] A. S. Levey, T. Greene, G. J. Beck, and M. S. Group, "A simplified equation to predict glomerular filtration rate from serum creatinine," *Journal of the American Society of Nephrology*, vol. 11, pp. A0828, 2000.
- [7] L. A. Stevens, J. Coresh, T. Greene, and A. S. Levey, "Assessing kidney function - measured and estimated glomerular filtration rate," *New England Journal of Medicine*, vol. 354, pp. 2473-2483, 2006.
- [8] R. W. Jelliffe and S. M. Jelliffe, "A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight," *Mathematical Biosciences*, vol. 14, pp. 17-24, 1972.
- [9] T. Le Bricon, E. Thervet, M. Froissart, M. Benlakehal, C. Legendre, and D. Erlich, "Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation," *Clinical Chemistry*, vol. 46, pp. 1206-1207, 2000.
- [10] D. DuBois and E. F. DuBois, "A formula to estimate the approximate surface area if height and weight are known," *Archives of Internal Medicine*, vol. 17, pp. 863-871, 1916.
- [11] R. W. Jelliffe, "Creatinine clearance: bedside estimate," *Annals of Internal Medicine*, vol. 79, pp. 604-605, 1973.
- [12] A. D. Rule, E. J. Bergstralh, J. M. Slezak, J. Bergert, and T. S. Larson, "Glomerular filtration rate estimated by cystatin C among different clinical presentations," *Kidney International*, vol. 69, pp. 399-405, 2006.
- [13] D. E. Salazar and G. B. Corcoran, "Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass," *American Journal of Medicine*, vol. 84, pp. 1053-1060, 1988.
- [14] G. L. Barbour, C. K. Crumb, C. M. Boyd, R. D. Reeves, S. P. Rastogi, and R. M. Patterson, "Comparison of inulin, iothalamate, and ^{99m}Tc -DTPA for measurement of glomerular filtration rate," *Journal of Nuclear Medicine*, vol. 17, pp. 317-320, 1976.
- [15] C. Lempert, "The chemistry of glycoamides," *Chemical Reviews*, vol. 59, pp. 667-736, 1959.
- [16] M. Wyss and I. Kaddurah-Daouk, "Creatine and creatinine metabolism," *Physiological Reviews*, vol. 80, pp. 1107-1213, 2000.
- [17] A. C. Baxmann, M. S. Ahmed, N. C. Marques, V. B. Menon, A. B. Pereira, G. M. Kirsztajn, and I. P. Heilberg, "Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C," *Clinical Journal of the American Society of Nephrology*, vol. 3, pp. 348-354, 2008.
- [18] M. H. Kroll, L. Nealon, M. A. Vogel, and R. J. Elin, "How certain drugs interfere negatively with the Jaffé reaction for creatinine," *Clinical Chemistry*, vol. 31, pp. 306-308, 1985.
- [19] O. Shemesh, H. Golbetz, J. P. Kriss, and B. D. Myers, "Limitations of creatinine as a filtration marker in glomerulopathic patients," *Kidney International*, vol. 28, pp. 830-838, 1985.
- [20] R. D. Perrone, N. E. Madias, and A. S. Levey, "Serum creatinine as an index of renal function: new insights into old concepts," *Clinical Chemistry*, vol. 38, pp. 1933-1953, 1992.
- [21] R. Swaminathan, P. Major, H. Snieder, and T. Spector, "Serum creatinine and fat-free mass (lean body mass)," *Clinical Chemistry*, vol. 46, pp. 1695-1696, 2000.
- [22] B. G. Keevil, E. S. Kilpatrick, S. P. Nichols, and P. W. Maylor, "Biological variation of cystatin C: implications for the assessment of glomerular filtration rate," *Clinical Chemistry*, vol. 44, pp. 1535-1539, 1998.
- [23] G. Filler, F. Priem, I. Vollmer, J. Gellermann, and K. Jung, "Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate," *Pediatric Nephrology*, vol. 13, pp. 501-505, 1999.
- [24] A. G. Christensson, A. O. Grubb, J.-Å. Nilsson, K. Norrgren, G. Sterner, and G. Sundkvist, "Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy," *Journal of Internal Medicine*, vol. 256, pp. 510-518, 2004.
- [25] D. Groesbeck, A. Köttgen, R. Parekh, E. Selvin, G. J. Schwartz, J. Coresh, and S. Furth, "Age, gender, and race effects on cystatin C levels in US adolescents," *Clinical Journal of the American Society of Nephrology*, vol. 3, pp. 1777-1785, 2008.
- [26] M. Yashiro, T. Kamata, H. Segawa, Y. Kadoya, T. Murakami, and E. Muso, "Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease," *Clinical and Experimental Nephrology*, vol. 13, pp. 598-604, 2009.
- [27] J. Stoves, E. J. Lindley, M. C. Barnfield, M. T. Burniston, and C. G. Newstead, "MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function," *Nephrology Dialysis Transplantation*, vol. 17, pp. 2036-2037, 2002.
- [28] J. Lin, E. L. Knight, M. L. Hogan, and A. K. Singh, "A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease," *Journal of the American Society of Nephrology*, vol. 14, pp. 2573-2580, 2003.
- [29] C. White, A. Akbari, N. Hussain, L. Dinh, G. Filler, N. Lepage, and G. A. Knoll, "Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods," *Journal of the American Society of Nephrology*, vol. 16, pp. 3763-3770, 2005.
- [30] J. S. Al Wakeel, D. Hammad, A. Al Suwaida, N. Tarif, A. Chaudhary, A. Isnani, W. A. Albedaiwi, A. H. Mitwalli, and S. S. Ahmad, "Validation of predictive equations for glomerular filtration rate in the Saudi population," *Saudi Journal of Kidney Diseases and Transplantation*, vol. 20, pp. 1030-1037, 2009.
- [31] S. Savaj, T. Shoushtarizadeh, M. A. Abbai, S. H. Razavimanes, and A. J. Ghods, "Estimation of glomerular filtration rate with creatinine-based versus cystatin C-based equations in kidney transplant recipients," *Iranian Journal of Kidney Disease*, vol. 3, pp. 234-238, 2009.
- [32] A. S. Levey, L. A. Stevens, C. H. Schmid, Y. Zhang, A. F. Castro, III, H. I. Feldman, J. W. Kusek, P. Eggers, F. Van Lente, T. Greene, and J. Coresh, "A new equation to estimate glomerular filtration rate," *Annals of Internal Medicine*, vol. 150, pp. 604-612, 2009.
- [33] S. Brown, "Re: Estimation of glomerular filtration rate with creatinine-based versus cystatin C-based equations in kidney transplant recipients," *Iranian Journal of Kidney Disease*, vol. 4, pp. 169-170, 2010.

- [34] J. R. Taylor, *An introduction to error analysis. The study of uncertainties in physical measurements*, 2nd ed. Sausalito: University Science Books, 1997.
- [35] V. Menon, M. G. Shlipak, X. Wang, J. Coresh, T. Greene, L. Stevens, J. W. Kusek, G. J. Beck, A. J. Collins, A. S. Levey, and M. J. Sarnak, "Cystatin C as a risk factor for outcomes in chronic kidney disease," *Annals of Internal Medicine*, vol. 147, pp. 19-27, 2007.
- [36] D. J. Newman, H. Thakkar, R. G. Edwards, M. Wilkie, T. White, A. O. Grubb, and C. P. Price, "Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine," *Kidney International*, vol. 47, pp. 312-318, 1995.
- [37] H. Li, G. Xu, X. Wang, X. Zhang, and J. Yanh, "Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes," *Chinese Medical Journal*, vol. 123, pp. 745-751, 2010.
- [38] U. Pöge, B. Stoffel-Wagner, H. U. Klehr, T. Sauerbruch, and R. P. Woitas, "Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients," *Nephrology Dialysis Transplantation*, vol. 21, pp. 660-664, 2006.
- [39] L. K. van Rossum, R. Zietse, A. G. Vulto, and Y. B. de Rijke, "Renal extraction of cystatin C vs ¹²⁵I-iothalamate in hypertensive patients," *Nephrology Dialysis Transplantation*, vol. 21, pp. 1253-1256, 2006.
- [40] H. Stowe, D. Lawrence, D. J. Newman, and E. J. Lamb, "Analytical performance of a particle-enhanced nephelometric immunoassay for serum cystatin C using rate analysis," *Clinical Chemistry*, vol. 47, pp. 1482-1485, 2001.
- [41] R. H. Laessig, S. S. Ehrmeyer, and J. E. Leinweber, "Intralaboratory performance requirements necessary to pass proficiency testing: CAP-1990 vs CLIA-1867 (March 14, 1990) formats compared," *Clinical Chemistry*, vol. 38, pp. 895-903, 1992.
- [42] M. A. McDowell, C. D. Fryar, C. L. Ogden, and K. M. Flegal, "Anthropometric reference data for children and adults: United States, 2003-2006," National Center for Health Statistics, Hyattsville 10, 2008.
- [43] F. Ceriotti, J. C. Boyd, G. Klein, J. Henny, J. Queraltó, V. Kairisto, and M. Panteghini, "Reference intervals for serum creatinine concentrations: assessment of available data for global application," *Clinical Chemistry*, vol. 54, pp. 559-566, 2008.
- [44] M. Peake and M. Whiting, "Measurement of serum creatinine – current status and future goals," *Clinical Biochemistry Reviews*, vol. 27, pp. 173-184, 2007.
- [45] R. Botev, J.-P. Mallié, C. Couchoud, O. Schüick, J.-P. Fauvel, J. F. M. Wetzels, N. Lee, N. G. De Santo, and M. Cirillo, "Estimating glomerular filtration rate: Cockcroft-Gault and modification of diet in renal disease formulas compared to renal inulin clearance," *Clinical Journal of the American Society of Nephrology*, vol. 4, pp. 899-906, 2009.